Problems for risk assessment of endocrine-active estrogenic compounds

Environmental Health Perspectives

Volumn 110, Issue SUPPL. 6, 2002, Pages 925-929

  Safe, Stephen H ^a   Pallaroni, Lea ^a   Yoon, Kyungsil ^a   Gaido, Kevin ^b   Ross, Susan ^b   McDonnell, Donald ^c  

^a TEXAS A AND M UNIVERSITY   (United States)

^b CIIT CENTERS FOR HEALTH RESEARCH   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Agonists; Antagonists; Estrogen receptor; Estrogens; Structure activity

Indexed keywords

4 HYDROXYTAMOXIFEN; 4 NONYLPHENOL; 4 TERT OCTYLPHENOL; 4,4' ISOPROPYLIDENEDIPHENOL; ANTIESTROGEN; AROMATIC HYDROCARBON RECEPTOR; BENZENE DERIVATIVE; BIPHENYL DERIVATIVE; CHLORDECONE; COMPLEMENT COMPONENT C3; ESTRADIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLAVONE DERIVATIVE; FLAVONOL DERIVATIVE; GENISTEIN; INDUSTRIAL CHEMICAL; ISOFLAVONE DERIVATIVE; LUCIFERASE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NARINGENIN; NONYLPHENOL; PHYTOESTROGEN; POLYCYCLIC AROMATIC COMPOUND; QUERCETIN; RALOXIFENE; RESVERATROL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TETRACHLOROBIPHENYL; TRICHLOROPHENOL DERIVATIVE;

BINDING AFFINITY; BINDING ASSAY; CELL ASSAY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENVIRONMENTAL EXPOSURE; ESTROGEN ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; OCCUPATIONAL TOXICOLOGY; PREDICTION; PRIORITY JOURNAL; REPORTER GENE; REVIEW; RISK ASSESSMENT; STANDARDIZATION; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION; WILD TYPE;

EID: 0036993511     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.02110s6925     Document Type: Review

References (62)

1. Ahlborg UG, Brouwer A, Fingerhut MA, Jacobson JL, Jacobson SW, Kennedy SW, Kettrup AAF, Koeman JH, Poiger H, Rappe C, et al. Impact of polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls on human and environmental health with special emphasis on application of the toxic equivalence factor concept. Eur J Pharmacol 228:179-199 (1992).
2. Birnbaum LS, DeVito MJ. Use of toxic equivalency factors for risk assessment for dioxins and related compounds. Toxilogy 105:391-401 (1995).
3. Safe S. Poychlorinated biphenyls (PCBs): environmental impact, biochemical and toxic responses, and implications for risk assessment. CRC Crit Rev Toxicol 24:87-149 (1994).
4. Safe S. Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs) and related compounds: environmental and mechanistic considerations which support the development of toxic equivalency factors (TEFs). CRC Crit Rev Toxicol 21:32-88(1990).
5. Ahlborg UG, Becking GC, Birnbaum LS, Brouwer A, Derks HJGM, Feeley M, Golor G, Hanberg A, Larsen JC, Liem AKD, et al. Toxic equivalency factors for dioxin-like PCBs. Chemosphere 28:1049-1067 (1994).
6. Safe S. Development, validation and problem with the TEF approach for risk assessment of dioxins and related compounds. J Anim Sci 76:134-141 (1998).
7. Safe S. Limitations of the toxic equivalency factor approach for risk assessment of TCDD and related compounds. Teratog Carcinog Mutagen 17:285-304 (1998).
8. Safe S. Hazard and risk assessment of chemical mixtures using the toxic equivalency factor (TEF) approach. Environ Health Perspect 106:1051-1058 (1998).
9. Silkworth JB, Brown JF Jr. Evaluating the impact of exposure to environmental contaminants on human health. Clin Chem 42:1345-1349 (1996).
10. Chen I, Safe S, Bjeldanes L. Indole-3-carbinol and diindolymethane as a aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Biochem Pharmacol 51:1069-1076 (1996).
11. Casper RF, Quesne M, Rogers IM, Shirota T, Jolivet A, Milgrom E, Savouret JF. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol 56:784-790 (1999).
12. Ciolino HP, Wang TT, Yeh GC. Diosmin and diosmetin are agonist of the aryl hydrocarbon receptor that differentially affect cytochrome P450 1A1 activity. Cancer Res 58:2754-2760 (1998).
13. Ciolino HP, Yeh GC. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol 56:760-767 (1999).
14. Gasiewicz TA, Kende AS, Rucci G, Willey JJ. Analysis of structural requirements for Ah receptor antagonist activity: elipticines, flavones, and related compounds. Biochem Pharmacol 52:1787-1803 (1996).
15. Ciolino HP, Daschner PJ, Yeh GC. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 58:5707-5712 (1998).
16. Ciolino HP, Daschner PJ, Yeh GC. Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem J 340:715-722 (1999).
17. Denison MS, Seidel SD, Rogers WJ, Ziccardi M, Winter GM, Heath-Pagliuso S. Natural and synthetic ligands for the Ah receptor. In: Molecular Biology Approaches to Toxicology (Puga A, Kendall RJ, eds). London:Taylor and Francis, 1998;3-33.
18. Gradelet S, Astorg P, Pineau T, Canivenc MC, Siess MH, Leclerc J, Lesca P. Ah receptor-dependent CYP1A induction by two carotenoids, canthaxanthin and β-apo-8-carotenal, with no affinity for the TCDD binding site. Biochem Pharmacol 54:307-315 (1997).
19. Jellinck PH, Forkert PG, Riddick DS, Okey AB, Michnovicz JJ, Bradlow HL. Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem Pharmacol 43:1129-1136 (1993).
20. Bjeldanes LF, Kim JY, Grose KR, Bartholomew JC, Bradfield CA. Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo-comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc Natl Acad Sci USA 88:9543-9547 (1991).
21. Colborn T, Vom Saal FS, Soto AM. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect 101:378-384 (1993).
22. Safe S. Endocrine disruptors and human health-is there a problem: an update. Environ Health Perspect 108:487-493 (2000).
23. Davis DL, Bradlow HL, Wolff M, Woodruff T, Hoel DG, Anton-Culver H. Medical hypothesis: xenoestrogens as preventable causes of breast cancer. Environ Health Perspect 101:372-377 (1993).
24. Sharpe RM, Skakkebaek NF. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract. Lancet 341:1392-1395 (1993).
25. Sharpe RM. Reproductive biology. Another DDT connection. Nature 375:538-539 (1995).
26. Food Quality Protection Act of 1996. Public Law 104-170. 1996.
27. Safe Drinking Water Act Amendments of 1996. Public Law 104-182. 1996.
28. Goldman JM, Laws SC, Balchak SK, Cooper RL, Kavlock RJ. Endocrine-disrupting chemicals: prepubertal exposures and effects on sexual maturation and thyroid activity in the female rat. A focus on the EDSTAC recommendations. Crit Rev Toxicol 30:135-196 (2000).
29. Stoker TE, Parks LG, Gray LE, Cooper RL. Endocrine-disrupting chemicals: prepubertal exposures and affects on sexual maturation and thyroid function in the male rat. A focus on the EDSTAC recommendations. Endocrine Disrupter Screening and Testing Advisory Commitee. Crit Rev Toxicol 30:197-252 (2000).
30. Verdeal K, Ryan DS. Naturally-occurring estrogens in plant foodstuffs-a review. J Food Prot 42:577-583 (1979).
31. Gaido K, Dohme L, Wang F, Chen I, Blankvoort B, Ramamoorthy K, Safe S. Comparative estrogenic activity of organochlorine pesticide residues in food and wine extracts. Environ Health Perspect 106:1347-1351 (1998).
32. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol 54:105-112 (1998).
33. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138:863-870 (1997).
34. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe S, Van der Saag PT, Van der Burg B, Gustafsson J-Å. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139:4252-4263 (1998).
35. McDonnell DP, Lieberman BA, Norris JA. Development of tissue-selective estrogen receptor modulators. In: Organ-Selective Actions of Steroid Hormones (Baird DT, Schutz G, Krattenmacher R, eds). Berlin:Springer-Verlag, 1995;1-28.
36. McDonnell DP. The molecular pharmacology of SERMs. Trends Endocrinol Metab 10:301-311 (1999).
37. Jordan VC. Targeted antiestrogens to prevent breast cancer. Trends Endocrinol Metab 10:312-317 (1999).
38. Smith CL, O'Malley BW. Evolving concepts of selective estrogen receptor action: from basic science to clinical applications. Trends Endocrinol Metab 10:299-300 (1999).
39. Fuqua SA, Russo J, Shackney SE, Stearns ME. Estrogen, estrogen receptors and selective estrogen receptor modulators in human breast cancer. J Women's Cancer 2:21-32 (2000).
40. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937 (1998).
41. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstorm O, Ohman L, Greene GL, Gustafsson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758 (1997).
42. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Throsell AG, Engstrom O, Ljunggren J, Gustafsson JA, Carlquist M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 18:4608-4618 (1999).
43. Norris JD, Paige LA, Christensen DJ, Chang C-Y, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, McDonnell DP. Peptide antagonists of the human estrogen receptor. Science 285:744-746 (1999).
44. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Change CY, Ballas LM, Hamilton PT, McDonnell DP, et al. Estrogen receptor (ER) modulators each induce distinct donformational changes in ERα and ERβ. Proc Natl Acad Sci USA 96:3999-4004 (1999).
45. Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, McDonnell DP. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140:5828-5840 (1999).
46. Klinge CM, Bowers JL, Kulakosky PC, Kamboj KK, Swanson, HI. The aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT) heterodimer interacts with naturally occuring estrogen response elements. Mol Cell Endocrinol 157:105-119 (1999).
47. Hall JM, Chang CY, McDonnell DP. Development of peptide antagonists that target estrogen receptor β-coactivator interactions. Mol Endocrinol 14:2010-2023 (2000).
48. Schaufele F, Chang CY, Liu WQ, Baxter JD, Nordeen SK, Wan YH, Day RN, McDonnell DP. Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and confactors to subnuclear domains containing the estrogen receptor. Mol Endocrinol 14:2024-2039 (2000).
49. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RG, Pike JW, McDonnell DP, Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21-30 (1994).
50. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distint classes of antiestrogens. Mol Endocrinol 9:659-669 (1995).
51. Jordan VC, Mittal S, Gosden B, Koch R, Lieberman ME. Structure-activity relationships of estrogens. Environ Health Perspect 61:97-110 (1995).
52. Katzenellenbogen JA. The structural pervasiveness of estrogenic activity. Environ Health Perspect 103:99-101 (1995).
53. Yoon K, Pallaroni L, Ramamoorthy K, Gaido K, Safe S. Ligand structure-dependent differences in activation of estrogen receptor α in human HepG2 liver and U2 osteogenic cancer cell lines. Mol Cell Endocrinol 162:211-220 (2000).
54. Yoon K, Pallaroni L, Stoner M, Gaido K, Safe S. Differential activation of wild-type and variant forms of estrogen receptor α by synthetic and natural estrogenic compounds using a promoter containing three tandem estrogen-responsive elements. J Steroid Biochem Mol Biol 78:25-32 (1998).
55. Gould JC, Leonard LS, Maness SC, Wagner BL, Connor K, Zacharewski T, Safe S, McDonnell DP, Gaido KW. Bisphenol A interacts with the estrogen receptor α in a distinct manner from estradiol. Mol Cell Endocrinol 142:203-214 (1998).
56. Ruh MF, Zacharewski T, Connor K, Howell J, Chen I, Safe S. Naringenin: a weakly estrogenic bioflavonoid which exhibits antiestrogenic activity. Biochem Pharmacol 50:1485-1493 (1995).
57. Gaido KW, Leonard LS, Maness SC, Galluzzo JM, McDonnell DP, Saville B, Safe S. Differential interaction of the methoxychlor metabolite HPTE with estrogen receptors alpha and beta. Endocrinology 140:5746-5753 (1999).
58. Gaido KW, Maness SC, McDonnell DP, Dehal SS, Kupfer D, Safe S. Interaction of methoxychlor and related compounds with estrogen recepto alpha and beta, and androgen recepto: Structure-activity studies. Mol Pharmacol 58:852-858 (2000).
59. Gehm BD, McAndrews JM, Chien P-Y, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94:14138-14143 (1997).
60. Lu RQ, Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol 179:297-304 (1999).
61. Mgbonyebi OP, Russo IH. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12:865-869 (1998).
62. Turner RT, Evans GL, Zhang M, Maran A, Sibonga JC. Is resveratrol an estrogen agonist in growing rats? Endocrinology 140:50-54 (1999).